Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder
| Status: | Withdrawn |
|---|---|
| Conditions: | Depression, Major Depression Disorder (MDD) |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 2/21/2018 |
| Start Date: | September 2015 |
| End Date: | February 2017 |
Combination of Anticholinergic and Glutamatergic Effects in Treatment-resistant Major Depressive Disorder. A Pilot Study
Ketamine infusions resulted in an acute reduction in global depression scores and in severity
of suicidal ideation. Scopolamine infusions produced also a significant improvement in
depression that was sustained over time.
We therefore plan to investigate the feasibility and efficacy of open-label repeated
intravenous administration of ketamine and scopolamine combined in this population of
severely depressed, treatment-resistant patients. The results from this study could lead to
the development of new strategies for the treatment of patients with TRD.
of suicidal ideation. Scopolamine infusions produced also a significant improvement in
depression that was sustained over time.
We therefore plan to investigate the feasibility and efficacy of open-label repeated
intravenous administration of ketamine and scopolamine combined in this population of
severely depressed, treatment-resistant patients. The results from this study could lead to
the development of new strategies for the treatment of patients with TRD.
Patients will undergo two weeks of prospective observation, they will then receive IV
infusions of ketamine, scopolamine or both per randomization as augmentation of their ongoing
antidepressant regime. The schedule of administration will be twice a week of three weeks.
After this phase the subject will be followed with assessments every two weeks for three
months.
infusions of ketamine, scopolamine or both per randomization as augmentation of their ongoing
antidepressant regime. The schedule of administration will be twice a week of three weeks.
After this phase the subject will be followed with assessments every two weeks for three
months.
Inclusion Criteria:
- Outpatients with sever treatment-resistant depression
- Currently depressed
- Currently under regular psychiatric care
- On an aggressive antidepressant regimen, stable for 4 weeks
Exclusion Criteria:
- No history of other major psychiatric illnesses, including bipolar disorder
- No history of psychosis
- No history of drug abuse
- No major medical illness or unstable medical condition.
We found this trial at
1
site
Click here to add this to my saved trials
